Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Phathom Pharmaceuticals yesterday and set a price target of $29.00. The company’s shares closed yesterday at $11.05.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Kluska is a 5-star analyst with an average return of 34.0% and a 48.46% success rate. Kluska covers the Healthcare sector, focusing on stocks such as Monopar Therapeutics Inc, Sarepta Therapeutics, and Skye Bioscience.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Phathom Pharmaceuticals with a $23.50 average price target.
PHAT market cap is currently $769M and has a P/E ratio of -2.34.
Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PHAT in relation to earlier this year. Last month, Robert Charles Breedlove, the CAO of PHAT sold 461.00 shares for a total of $5,573.49.
Read More on PHAT:
/Amazon%20-%20Image%20by%20bluestork%20via%20Shutterstock.jpg)
/Apple%20Inc%20logo%20on%20Apple%20store-by%20PhillDanze%20via%20iStock.jpg)
/A%20Palantir%20sign%20displayed%20on%20an%20office%20building%20by%20Poetra_RH%20via%20Shutterstock.jpg)
